News
TERN
5.86
-3.14%
-0.19
Weekly Report: what happened at TERN last week (1216-1220)?
Weekly Report · 1d ago
Terns Pharmaceuticals Positioned for Success with Promising Oral Therapy TERN-601 Amid Novo Nordisk’s Setback
TipRanks · 3d ago
Mizuho Securities Reaffirms Their Buy Rating on Terns Pharmaceuticals (TERN)
TipRanks · 3d ago
Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers
Seeking Alpha · 5d ago
Weekly Report: what happened at TERN last week (1209-1213)?
Weekly Report · 12/16 09:18
"Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Benzinga · 12/13 16:16
Insider Spends US$110k Buying More Shares In Terns Pharmaceuticals
Simply Wall St · 12/11 11:00
Insider Purchase: Chief Executive Officer of $TERN (TERN) Buys 15,450 Shares
Barchart · 12/10 03:30
Weekly Report: what happened at TERN last week (1202-1206)?
Weekly Report · 12/09 09:17
Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE) and Terns Pharmaceuticals (TERN)
TipRanks · 12/06 06:30
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), Cartesian Therapeutics (RNAC) and Terns Pharmaceuticals (TERN)
TipRanks · 12/06 06:11
Hold Rating on Terns Pharmaceuticals’ TERN-701 Due to Uncertain Efficacy Despite Promising Safety Profile
TipRanks · 12/05 16:04
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN), Trevi Therapeutics (TRVI) and Vigil Neuroscience Inc (VIGL)
TipRanks · 12/05 15:32
Buy Rating for Terns Pharmaceuticals Driven by Promising TERN-701 Efficacy and Safety
TipRanks · 12/05 15:32
Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
Seeking Alpha · 12/04 19:41
Terns’s stock soars as analysts cheer leukemia data — and predict more gains
MarketWatch · 12/04 18:18
Terns Pharmaceuticals Price Target Maintained With a $20.00/Share by JMP Securities
Dow Jones · 12/04 16:31
JMP Securities Reiterates Market Outperform on Terns Pharma, Maintains $20 Price Target
Benzinga · 12/04 16:22
TERNS PHARMACEUTICALS INC. <TERN.O>: OPPENHEIMER RAISES TARGET PRICE TO $20 FROM $17
Reuters · 12/04 13:08
HC Wainwright & Co. Reiterates Neutral on Terns Pharma, Maintains $7.5 Price Target
Benzinga · 12/04 11:57
More
Webull provides a variety of real-time TERN stock news. You can receive the latest news about Terns Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.